DAYBU nears EU green light, unlocking US$35m upfront for Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) says the European Medicines Agency’s CHMP has adopted a positive opinion, after re‑examination, recommending the European Commission grant marketing authorisation for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five and over.




_1429853_640x360_2505037379572-640x360.webp&w=3840&q=75)
_1429851_640x360_2505035843852-640x360.webp&w=3840&q=75)



_1429843_640x360_2505035843839-640x360.webp&w=3840&q=75)

